Oct 31st Day 3

09:09

International Partnerships & DCVMs

09:09

Manufacturing Practices

09:09

Oncolytic Viruses

09:09

Prevention & Response: Infectious Diseases

09:09

Vaccine Safety & Decision Making

Vaccine Safety
09:10

Panel: Building vaccine confidence and resilient immunization systems – The role of communications

  • The role of communications in vaccine hesitancy and confidence?
  • How can stakeholders from patient advocates, journalists, healthcare providers, policymakers to industry
  • Apply behavioural science insights to shape more effective communications around vaccination and improve vaccination acceptance?
  • What are the attributes of a resilient immunization system, and how can we collaborate to manage threats to vaccine confidence and better anticipate and mitigate issues in the future?
Partnerships
10:10

EIB Venture Debt – Financing Innovation and Growth in Life Sciences

  • How the European Investment Bank and the EU Join Forces to Fight Infectious Diseases and Support Innovative European SMEs
10:40

Morning Networking Break

11:19

Antibody Therapy

Vaccine Safety
11:20

Adult Vaccines – What’s needed for a rapidly changing demographic?

  • Same data, different results: an archetype analysis of adult vaccine decision making and uptake in 34 countries
  • Adult Immunization Evidence & Policy: Issues for the next decade
  • Issues for implementation of adult immunization programs
  • Introducing the International Council on Adult Immunization
  • Panel with all speakers: Accelerating progress – what do we do differently?
Immuno-oncology
11:20

Overcoming antibody drug development challenges

-Translating antibody therapies to the clinic – The devil is in the detail
Immuno-oncology
12:20

Q & A with speakers

12:50

Afternoon Networking Lunch

13:49

AFTERNOON PLENARY TALKS

Dr Jonathan Van-Tam
14:00

What’s next? Working towards Immunology 2.0 and beyond

  • How has genomics, virology and epidemiology helped revolutionise the way we develop vaccines?
  • New scientific approaches to more targeted bacterial vaccines using computational modelling and mAb mapping
  • What progress has been made with all this new information to hand – is it translational?
  • What policy considerations and challenges should we anticipate with these technologies? Governmental challenges
Panel discussion
15:00

Eliminating (or Eradicating) Measles and other Global Infectious Diseases

  • Is elimination of measles still viable?
  • What’s the vaccinations strategy to get there and how do we maintain this once a disease is eradicated?
  • What plans are in place for developing countries?
Dr Kutub Mahmood, Scientific Director, Path
16:00

Chair’s closing remarks and close of congress

last published: 04/Nov/19 16:05 GMT